What is the optimal dose and fractionation schedule of prophylactic cranial irradiation in patients with extensive stage SCLC?
What is the optimal dose and fractionation schedule of prophylactic cranial irradiation in patients with extensive stage SCLC?
The Prophylactic Cranial Irradiation Overview Collaborative Group meta-analysis of individual patient data from seven trials included mostly patients with limited stage SCLC although a minority had extensive stage SCLC.[1] This analysis confirmed a reduction in the incidence of brain metastases with increasing doses of prophylactic cranial irradiation (PCI), but no effect on survival.
A randomised EORTC trial of PCI in patients with extensive stage SCLC utilised a range of PCI doses and fractionation schemes, the commonest of which were 20Gy/5Fr, 30Gy/10Fr, 30Gy/12Fr and 25gy/10Fr.[2] Sixty two percent of patients received 20Gy/5Fr. However, allocation to radiotherapy dose/fractionation schedule was not randomised.
As such, the optimal radiotherapy dose and fractionation schedule for extensive stage SCLC has not yet been defined.
Evidence summary and recommendations
Evidence summary | Level | References |
---|---|---|
Prophylactic cranial radiotherapy schedules ranging from 20Gy in 5 fractions to 30Gy in 12 fractions reduce the incidence of brain metastases and improve survival in extensive stage SCLC patients who achieve a response to initial therapy.
Last reviewed November 2015 |
II | [2] |
Over this dose range, higher radiotherapy doses confer no survival advantage over lower ones
Last reviewed November 2015 |
I | [1] |
References
- ↑ 1.0 1.1 Prophylactic Cranial Irradiation Overview Collaborative Group. Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission (review). Cochrane Database Syst Rev 2009 Jan Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002805/pdf.
- ↑ 2.0 2.1 Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007 Aug 16;357(7):664-72 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17699816.